AVEO Pharmaceuticals Inc - Articles and news items

MAA submitted for tivozanib for the treatment of RCC

Industry news / 1 March 2016 / Victoria White

Tivozanib is an oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI)…

AVEO receives European regulatory guidance regarding potential marketing authorisation application for tivozanib

Industry news / 4 June 2015 / Victoria White

AVEO has received confirmation of support from two CHMP members following pre-submission meetings to discuss the potential submission of a MAA for tivozanib…

Astellas logo
Boehringer Ingelheim logo

Boehringer Ingelheim and AVEO announce manufacturing agreement for ficlatuzumab

Industry news, News / 1 December 2011 / Boehringer Ingelheim

AVEO & Boehringer Ingelheim enter into an agreement…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...